Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial

By sjmartinez • November 14, 2024

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial. Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093/cid/ciae551. Epub ahead of print. PMID: 39523543.

Tags: COVID-19 drug therapy, EPIC-HR, Infectious Diseases, nirmatrelvir, Publications, ritonavir, Symptoms

Secretion of the Francisella pathogenicity island effector protein PdpE requires components of both the Sec and Type IV pilus secretion pathways

Lee B-Y, Clemens DL, Horwitz MA. Secretion of the Francisella pathogenicity island effector protein PdpE requires components of both the Sec and Type IV pilus secretion pathways.[...]

Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum

Dong HV, Salem GM, Kerin T, Tang KH, Cortado R, Shin-Sim M, Arnold EM, Swendeman D, Tobin NH, Rimoin AW, Aldrovandi GM, Yang OO, Bryson[...]

MUCOR-ADVANCE: Uniting multidisciplinary science to defeat a deadly fungus

Wurster S, Stewart AG, Gu Y, Youssef EG, John TM, Uppuluri P, Chamilos G, Filler S, Bruno V, Ibrahim AS, Kontoyiannis DP; MUCOR-ADVANCE consortium. MUCOR-ADVANCE:[...]